Several biopharma companies announced clinical updates, financial results, strategic partnerships, and operational changes. Highlights include Moderna's 10% workforce reduction amid revenue slowdown, Alnylam's strong sales growth for its rare disease drug Amvuttra, and Guardant Health raising full-year revenue guidance following a 31% Q2 increase. AbbVie reported revenue beats and expanded M&A interests, with high expectations for its drug portfolio. These developments reflect ongoing shifts in biotech financial health and strategic refocusing.